Pfizer joins Mission's £20m series B
Mission Therapeutics can boast another top pharma corporate venture capital investor following its latest financing, a £20m series B round.
Mission Therapeutics can boast another top pharma corporate venture capital investor following its latest financing, a £20m series B round.